Viridian Therapeutics, Inc. (VRDN) on Tuesday announced positive topline results from the Phase 3 REVEAL-2 study of elegrobart in patients with chronic thyroid eye disease, sending its shares up more than 25% in pre-market trading.
The study met its primary endpoint for both the U.S. Food and Drug Administration and the European Medicines Agency with high statistical significance.
REVEAL-2 also achieved all key secondary endpoints related to proptosis in both the every-four-week (Q4W) and every-eight-week (Q8W) treatment arms, while the Q4W arm demonstrated a statistically significant improvement in diplopia responder rate at week 24. The efficacy profile was generally consistent across patients regardless of baseline Clinical Activity Score.
Elegrobart was generally well tolerated in the study.
The company said it expects to submit a Biologics License Application for elegrobart in the first quarter of 2027.
Viridian shares closed at $14.06 on Monday, up 4.77%.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.